In the BRIGHSTAR single-arm phase I study (N = 34), patients with ALK-rearranged NSCLC (not all oligometastatic) received brigatinib for 8 weeks followed by LCT (radiation or surgery) [56]. Here, ALK is linked to non-small cell lung carcinoma.